68Ga-based PSMA radiopharmaceuticals have been extensively evaluated in the clinic, leading to FDA approval for [68Ga]Ga-PSMA-11 in December 2020 for PET imaging of PSMA positive lesions in men with prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.